Professionals 224 Users Online

Liposomes Market

Rising Demand for Targeted Drug Delivery Systems Boosting Liposomes Market

Liposomes Market By Product (Simple Liposomes, Formulated Liposomes and Vaccines)

Liposomes Market Outlook (2023 to 2033)

In 2022, the Global Liposomes Market reached a valuation of around US$ 6.7 Billion, with the global market expected to grow at a CAGR of 6.2% to reach a valuation of around US$ 13.0 Billion by the end of 2033.

Market Size (2023)

US$ 7.1 Billion

Projected Market Value (2033)

US$ 13.0 Billion

Global Market Growth Rate (2023 to 2033)

6.2% CAGR

Market Share of Top 5 Countries


As assessed by Persistence Market Research, drug delivery segment held a market share of around 91.0% in the global market, in 2022. Overall, liposomes market sales account for around 19.3% of revenue share in the Global Drug Delivery Systems Market, which was valued at around US$ 39.3 Billion in 2022.

Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Sales Analysis of Market from 2015 to 2022 Vs Market Outlook for 2023 to 2033

The global market recorded a historic CAGR of 3.9% in the last 7 years from 2015 to 2022.

The number of chronic diseases, cancer diseases, expanding public awareness of physical well-being, and an increase in the prevalence of lifestyle diseases including diabetes and obesity-related disorders have all contributed to an increase in the global demand for pharmaceuticals. This has increased the demand for liposomal drugs for the treatment of various life threatening diseases.

  • It is thought that liposomes can help active pharmaceutical ingredients attain improved functionality, such as a longer shelf life, and can also give formulations an advantage.

The market for medicinal liposomal formulations generally lacks specific government regulations governing ethical production and distribution practices. The availability of higher-quality ingredients for drug manufacture will increase as more players begin to conform by the manufacturing and distribution standards set by the International Pharmaceutical Excipient Council (IPEC). Additionally, it is anticipated that initiatives by governments and regulatory bodies in developed countries like the United States and the United Kingdom to speed up the approval process for liposomal formulation will further promote market growth.

liposomes are making their way into medical sciences. One of the applications is the topical administration of liposomes for the treatment of dermal conditions. Liposomal nanotechnology will become a more dependable manufacturing platform as technology evolves, especially in the fields of public health and medical diagnostics. Participants in the global market are therefore anticipated to experience profitable growth opportunities throughout the forecast period.

The Global Liposomes Market is likely to show high growth over the coming years at a CAGR of 6.2% and reach a global market size of US$ 13.0 Billion by 2033.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

How Can the Global Market Grow?

Technological Advancements in Liposomal Drug Delivery Systems and Frequent Approvals of Liposomal Pharmaceuticals

Employing substances at the nanoscale to diagnose and treat diseases, nanomedicine is a rapidly expanding field. Numerous preclinical and clinical studies that demonstrate fewer adverse effects, better treatment outcomes, and site-specific drug delivery indicate how nanomedicines overcome the drawbacks of conventional treatment. A lot of attention has been paid in recent years to the promising intersection of pharmaceutical science and nanoscience. Controlled drug delivery methods frequently use organic, inorganic, metallic, and polymeric nanostructures such macro-emulsions, dendrimers, nanomaterials, liposomes, and solid lipid nanoparticles (SLNs). Liposomes are seen to be one of the most promising drug delivery methods due to their small size, biocompatibility, and chemical composition and stability.

In developing countries like India, Mexico, and Brazil, growing patient population for chronic diseases as well as skin diseases. These countries present a significant market opportunity for pharmaceuticals and medicines. Increase in patient disposable income and economic growth in these emerging markets will assist in ensuring the market's long-term sustainability.

  • Additionally, strengthening healthcare infrastructure and increasing healthcare expenditure by the relevant governments would help to increase the rate of people seeking treatment. The demand for pharmaceuticals and medications would rise as a result, consequently leading to market growth.

Similarly, availability of healthcare products and medications will stimulate the development of the liposomes market as well.

A variety of liposome-based formulations are now available for human use as a result of significant advancements in liposome technology, and many more are presently undergoing various clinical trials. Several medications' therapeutic index have enhanced as a result of liposomal encapsulation, primarily due to changes in their pharmacodynamics and pharmacokinetics. In an effort to maximize drug delivery by maintaining the therapeutic agent's unique capabilities while minimizing its shortcomings, many liposomal drug delivery techniques have evolved distinctive properties.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

Can the Market Growth Be Affected in Any Way?

“Presence of Few Market Players to Increase Supply-Demand Gap”

For high purity liposomal excipients, which could help in the development of lipid-based pharmaceuticals, there is a significant supply-demand gap. Basic drugs for the treatment of chronic diseases such as cancer and cardiovascular diseases use liposomal excipients. The need for lipid-based medicines will expand as the number of cancer and cardiovascular patients rises. However, the gap between supply and demand will keep growing because there are few manufacturers in the market which will ultimately hamper the market.

Research and development efforts related to innovative liposomal formulation are being hindered by the lack of separate guidelines for the manufacture and approval of liposomes. In accordance with current regulatory guidelines, if a new drug is rejected, the excipient is also rejected, even if there is no connection between the failure and the excipient.

  • The clinical trial data from that failed formulation is useless. Due to this, both the manufacturer of the excipients and the drug sustain significant financial losses. Manufacturers find it unprofitable to develop innovative formulations under adequate regulatory compliances in terms of both cost and timeline, which restricts their chances of having a novel excipient approved, which provides hindrance to the market.
Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Country-wise Insights

Why is the U.S. Market Booming?

“Presence of Well Established Healthcare Infrastructure”

The U.S. accounted for around 92.4% market share in the North America market in 2022.

Due to the high prevalence of chronic diseases in the country, the presence of a strong healthcare infrastructure, and the presence of some of the leading market players in the country, the U.S. is anticipated to dominate the liposomes market throughout the forecast period.

  • For instance, over 1.9 million new instances of cancer and over 609,360 cancer-related deaths were predicted in the U.S. by the end of 2022, according to the American Cancer Society's 2022 report.
  • According to the same source, cancer is the second leading cause of death in the U.S. As a result, there is a high need for advanced therapeutics in the nation, which is anticipated to positively affect the expansion of the liposomes market there.

Will the Germany Be a Lucrative Market for Liposomes?

“Rigorous Research and Development Activities in the Field of Lipid Pharmaceuticals”

The Germany market held around 26.7% market share of the Europe market in 2022.

Germany’s strong research and development efforts in developing liposomal drugs in application of cardiovascular diseases (CVDS) is expected to drive the market further in Germany. Drugs and other pharmacological substances for cardiovascular uses can well be delivered via liposomes. Future developments in this developing subject include improvements in the body's ability to target substances, as well as the development of theranostic liposomes that can treat cardiac disorders.

  • In Germany, cardiovascular disorders account for over 40% of all deaths, making it the leading cause of death. According to WHO, CVDs are also linked to serious health implications for the people and lead to huge medical expenses for society.

Thus, development of novel liposomal medications will aid in maintaining the prevalence of CVDs and reduce the expenses of expensive treatments in the nation.

How is China Emerging as a Prominent Market?

“Growing Prevalence of Chronic Diseases as Well as Market Penetration of Key Players”

China held a market share of about 49.9% of the East Asia market in 2022.

Growing prevalence of chronic diseases, increasing geriatric population, presence of vast patient pool, and market penetration of international players are factors expected to boost the market in China.

There is growing demand for novel medications such as liposomal drugs for the treatment various chronic disorders as the patient pool is increasing at a significant rate.

  • In 2022, an article in the journal of the American Medical Directors Association stated that 81.1% of older Chinese people in the country had one or more chronic conditions. The incidence rose with advancing age and peaked between the ages of 80 and 84. Older adults in China had a high prevalence of chronic diseases.

Category-wise Insights

Which Product is Driving the Demand within the Global Market?

“Increasing Utilization of Liposomes in Drug Formulations”

The formulated liposomes held around 68.9% share of the total market in 2022.

Drug delivery to target sites is made easier by the use of formulated liposomes. Both negatively and positively charged compounds can form complexes with liposomes. The segment is expected to grow in the future as liposomes provide protection for the DNA against deteriorating processes as well, due to mentioned advantages of liposomal drugs, these are extensively used drug formulations.

Which Application is Driving the Demand for Liposomes Market?

“Growing Application of Liposome Drug Delivery Systems in Treating Various Diseases”

The drug delivery segment held around 91.0% share of the total market in 2022.

The liposome drug delivery is an emerging field and has gained serious attraction in the rug delivery scenario, this method uses nanoscale components such as biocompatible nanoparticles and nanotechnology to transport drugs to the targeted location in order to prevent and treat a variety of diseases.

  • For drug delivery systems, a variety of bio polymeric nanoparticles, including chitosan, xanthan gum, cellulose, and others, can be used.

Liposome drug delivery is one of the most effective options for drug delivery, due to it is expected to hold the largest market share during the course of the forecast.

Which is the Leading Distribution Channel Within the Global Market?

“High Demands for Liposomal Drugs via Pharmacies”

Distribution sales segment held around 90.2% share of the total market in 2022.

Owing to high prevalence of various chronic and skin diseases, there is high demand pharmaceuticals including liposomal drugs to for therapeutic purposes.

  • A significant factor driving the segment is the high prevalence of chronic disease. According to WHO estimates, non-communicable diseases (NCDs) account for 41 million deaths each year, or 74% of all deaths worldwide. Eighty-six percent of the 17 million premature deaths caused by NCDs each year actually occur in low- and middle-income nations. The majority of NCD deaths are caused by cardiovascular diseases, which are followed by cancers (9.3 million), and chronic respiratory diseases.

Competition Landscape

Leading players in this market have adopted a variety of strategies, od which some key strategies opted includes collaborations and introduction of new products.

Some key instances of development include:

  • In Jan 2022, in compliance with a development and opportunity Agreement signed by Pfizer Inc. and Acuitas Therapeutics, Pfizer had the option of development of vaccines with Acuitas’ lipid nanoparticle (LNP) technology.
  • In Oct 2021, a new version of Evonik's LIPEX® liposome extruders were introduced. For drug designers and manufacturers, LIPEX® Flow offers a better solution for bringing liposomal pharmaceuticals to market.

Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the liposomes market, which are available in the full report.

Liposomes Industry Report Scope



Forecast Period

2023 to 2033

Historical Data Available for

2015 to 2022

Market Analysis

USD Million for Value

Key Countries Covered

  • United States
  • Canada
  • Brazil
  • Argentina
  • Mexico
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • India
  • Thailand
  • Malaysia
  • Indonesia
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Türkiye
  • GCC Countries
  • North Africa
  • South Africa

Key Market Segments Covered

  • Product
  • Application
  • Distribution Channel
  • Region

Key Companies Covered

  • Novartis AG (Liposoma BV)
  • Precision NanoSystems Inc
  • Janssen Pharmaceutical Companies (Johnson & Johnson
  • Encapsula Nano Sciences
  • Synpac-Kingdom Pharmaceutical Co., Ltd
  • Celsion GmbH
  • Gilead Sciences, Inc
  • Pacira BioSciences, Inc.
  • Luye Pharma Group
  • Sun Pharma Industries Ltd
  • Shanghai New Asia Pharmaceutical Co., Ltd.
  • Creative Biolabs
  • Nanovex Biotechnologies SL
  • Insys Therapeutics Inc
  • Fujifilm Holdings Corporation
  • Virpax Pharmaceuticals
  • Azaya Therapeutics
  • Avanti Polar Lipids, Inc.
  • Breath Therapeutics (Zambon company)
  • Getwell
  • Taiwan Liposome Company Ltd
  • Fresenius Health Care Group
  • Xellia Pharmaceuticals (Novo Holdings A/S)
  • Jazz Pharmaceuticals plc
  • Ipsen Biopharmaceuticals, Inc.
  • Baxter
  • GMPriority Pharma
  • S. G. Biopharm Pvt. Ltd

Report Coverage

  • Market Forecast
  • Competition Intelligence
  • DROT Analysis
  • Market Dynamics and Challenges
  • Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Key Segments Covered in Liposomes Industry Research


  • Simple Liposomes
  • Formulated Liposomes
    • Doxorubicin Liposomes
    • Amphotericin B Liposomes
    • Paclitaxel Liposomes
    • Cytarabine Liposomes
    • Irinotecan Liposomes
    • Cisplatin Liposomes
    • Others
  • Vaccines


  • Drug delivery
    • Cancer
    • Fungal Infection
    • Viral & Parasite Infection
    • Others
  • Gene Delivery/Transfection
  • Contrast agents for medical imaging
  • Model Cell Membranes

Distribution Channel:

  • Retail Sales
    • Academic & Research Laboratories
    • Biopharmaceutical Companies
    • Clinical Research Organizations
    • Others
  • Distributional Sales
    • Hospital Pharmacies
    • Retail Pharmacies
    • Mail Order Pharmacies
    • Drug Stores


  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

- Companies Covered in This Report -

  • Novartis AG (Liposoma BV)
  • Precision NanoSystems Inc
  • Janssen Pharmaceutical Companies (Johnson & Johnson)
  • Encapsula Nano Sciences
  • Synpac-Kingdom Pharmaceutical Co., Ltd
  • Celsion GmbH
  • Gilead Sciences, Inc
  • Pacira BioSciences, Inc.
  • Luye Pharma Group
  • Sun Pharma Industries Ltd
  • Shanghai New Asia Pharmaceutical Co., Ltd.
  • Creative Biolabs
  • Nanovex Biotechnologies SL
  • Insys Therapeutics Inc
  • Fujifilm Holdings Corporation
  • Virpax Pharmaceuticals
  • Azaya Therapeutics
  • Avanti Polar Lipids, Inc.
  • Breath Therapeutics (Zambon company)
  • Getwell
  • Taiwan Liposome Company Ltd
  • Fresenius Health Care Group
  • Xellia Pharmaceuticals (Novo Holdings A/S)
  • Jazz Pharmaceuticals plc
  • Ipsen Biopharmaceuticals, Inc.
  • Baxter
  • GMPriority Pharma
  • S. G. Biopharm Pvt. Ltd

- Frequently Asked Questions -

The global market is currently valued at around US$ 6.7 Billion in 2022.

The global market is set to reach a valuation of around US$ 7.1 Billion by the end of 2023.

Sales of the market are set to witness growth at a CAGR of 6.2% and be valued at around US$ 13.0 Billion by 2033.

Demand for the global market increased at an 3.9% CAGR from 2015 to 2022.

The U.S., Germany, China, the U.K., and France account for most demand within the market, currently holding around 58.7% market share.

The U.S. accounts for around 92.4% share of the North American market in 2022.

China held a market share of about 49.9% of the East Asia market in 2022.

The Germany market held around 26.7% market share of the Europe market in 2022.

Novartis AG, Precision NanoSystems Inc, Janssen Pharmaceutical Companies, Encapsula Nano Sciences, Gilead Sciences, Inc, Sun Pharma Industries Ltd, Creative Biolabs, Fresenius Health Care Group, Baxter, are among others are the key players in the global market.

Increasing geriatric population, increasing research and development efforts in developing novel liposomal drugs, and growing prevalence of chronic diseases are few of the factors propelling the global market.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate